Suspended

PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Pembrolizumab (PD-1 Blocking Antibody)

Drug
Who is being recruted

Lymphoma+3

+ Lymphoma, Non-Hodgkin

+ Neoplasms

From 14 to 70 Years
+23 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: February 2017
See protocol details

Summary

Principal SponsorMingzhi Zhang
Study ContactMingzhi Zhang, Pro,Dr
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 19, 2017

Actual date on which the first participant was enrolled.

Patients with relapsed or refractory NK/T cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy. The investigators have been proceeding this trial to evaluate the efficacy and safety of the immune checkpoint inhibitor PD-1 blockade, pembrolizumab in the patients with relapsed or refractory NK/T cell lymphoma.

Official TitlePD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma
NCT03107962
Principal SponsorMingzhi Zhang
Study ContactMingzhi Zhang, Pro,Dr
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 14 to 70 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

LymphomaLymphoma, Non-HodgkinNeoplasmsNeoplasms by Histologic TypeLymphoma, T-CellLymphoma, Extranodal NK-T-Cell

Criteria

11 inclusion criteria required to participate
Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time > 3 months
Histological confirmed evidence of relapsed or refractory NK/T cell lymphoma
Before enrollment, representative formalin-fixed paraffin-embedded tumor samples (or 15 tissue sections at least) and related pathological reports are needed
Previous treatment with at least one chemotherapy regimen
Show More Criteria
12 exclusion criteria prevent from participating
Disagreement on blood sample collection
Patients allergic of chimeric or humanized antibody
Pregnant or lactating women
Serious medical illness likely to interfere with participation
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Pembrolizumab

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Oncology Department of The First Affiliated Hospital of Zhengzhou University

Zhengzhou, ChinaOpen Oncology Department of The First Affiliated Hospital of Zhengzhou University in Google Maps
SuspendedOne Study Center